Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpointsVTP-300 is the first antigen-specific immunotherapy shown to induce...
Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpointsVTP-300 is the first antigen-specific immunotherapy shown to induce...
KET01 Phase 2 Clinical Trial with Topline Results Expected Mid-YearMUNICH, Germany, March 28, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health...
-The distinction recognizes faculty who have demonstrated success in translating research into a commercial setting-BOSTON and ATHENS, Ga., March 28,...
LY Research Patent # US 8,114,444 B2 is Valued at US$210,000,000 LAS VEGAS, NV, March 28, 2023 (GLOBE NEWSWIRE) --...
Real-World Evidence Demonstrates the Highest Response and Remission Rates Observed to Date for Deep BURLINGTON, Mass. and JERUSALEM, March 28, 2023...
BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, has entered into an exclusive...
PURCHASE, NY, March 25, 2023 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, is...
Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory...
SAINT LAURENT, Quebec, March 24, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films,...
Conference Call to be held Friday, March 31, at 9:00am Eastern TimeATLANTA, March 24, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences,...
Conference call to be held on Thursday, March 30 at 8:30 a.m. ETROCKVILLE, Md., March 24, 2023 (GLOBE NEWSWIRE) --...
First TIL Therapy BLA Submission to U.S. Food and Drug AdministrationSAN CARLOS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Iovance...
HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense...
MONTRÉAL, March 24, 2023 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a...
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000...
Bagsværd, Denmark, 24 March 2023 – Novo Nordisk today announced headline results from the PIONEER PLUS trial, a phase 3b,...
DENVER, March 24, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca RatonBOCA RATON, Fla. and VIENNA, Austria, March...
Westport, CT, March 24, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital...
Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue...